{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:07:01Z","timestamp":1765667221893},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.lpm.2017.09.029","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T06:57:49Z","timestamp":1519369069000},"page":"e9-e13","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Romain","family":"Freund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Francois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guislaine","family":"Carcelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2017.09.029_bib0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-\u03b1 inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"15","key":"10.1016\/j.lpm.2017.09.029_bib0100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2017.09.029_bib0105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.lpm.2017.09.029_bib0110","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti\u2013tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.lpm.2017.09.029_bib0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.lpm.2017.09.029_bib0120","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.lpm.2017.09.029_bib0125","article-title":"Pr\u00e9vention et prise en charge de la tuberculose en, France. Synth\u00e8se et recommandations du groupe de travail du conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France (2002\u20132003)","volume":"20","year":"2003","journal-title":"Rev Mal Respi"},{"key":"10.1016\/j.lpm.2017.09.029_bib0130","unstructured":"Health C for D and R. Recently-approved devices \u2013 QuantiFERON\u00ae \u2013 TB \u2013 P010033, 2001 [Internet]. [cited 2015 Aug 17]. Available from: http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/DeviceApprovalsandClearances\/Recently-ApprovedDevices\/ucm084025.htm."},{"issue":"12","key":"10.1016\/j.lpm.2017.09.029_bib0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.lpm.2017.09.029_bib0140","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic anti-tuberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.lpm.2017.09.029_bib0145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2017.09.029_bib0150","unstructured":"Updated guidelines for using interferon-gamma release assays to detect mycobacterium tuberculosis infection \u2013 United States, 2010 [Internet]. [cited 2015 Aug 17]. Available from: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5905a1.htm?s_cid=rr5905a1_e."},{"year":"2015","series-title":"Tests in vitro de d\u00e9pistage de l\u2019infection tuberculeuse latente par d\u00e9tection de production d\u2019interf\u00e9ron gamma","key":"10.1016\/j.lpm.2017.09.029_bib0155"},{"year":"2011","series-title":"Tuberculose et tests de d\u00e9tection de l\u2019interf\u00e9ron gamma. Commission sp\u00e9cialis\u00e9e maladies transmissibles","key":"10.1016\/j.lpm.2017.09.029_bib0160"},{"key":"10.1016\/j.lpm.2017.09.029_bib0165","unstructured":"Table National de Codage de biologie, 2017 [Internet]. [cited 2015 Aug 17]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/nabm\/index_presentation.php?p_site=AMELI."},{"key":"10.1016\/j.lpm.2017.09.029_bib0170","unstructured":"R\u00e9f\u00e9rentiel des actes hors nomenclature, 2017 [Internet]. [cited 2015 Aug 17]. Available from: http:\/\/www.chu-montpellier.fr\/fr\/biologie-pathologie\/referentiel-des-actes\/."},{"issue":"5","key":"10.1016\/j.lpm.2017.09.029_bib0175","first-page":"603","article-title":"Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs","volume":"12","author":"Fonseca","year":"2006","journal-title":"Rev Port Pneumol"},{"issue":"6","key":"10.1016\/j.lpm.2017.09.029_bib0180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF03256394","article-title":"Cost-effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-\u03b1 antagonist therapy","volume":"14","author":"Kowada","year":"2010","journal-title":"Mol Diagn Ther"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218300149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218300149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T21:56:12Z","timestamp":1535061372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498218300149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0755498218300149"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2017.09.029","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}